AstraZeneca PLC (AZN): Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand AstraZeneca PLC (AZN)

A stable geopolitical backdrop and humanitarian status protect AstraZeneca PLC (AZN) assets from trade conflicts. The behemoth is betting on costly R&D in molecular biology to combat cancer. High medical authority confirms its status as an oncology flagship. The historical PEG level demonstrates valuation dynamics, where 1.50 serves as the current metric, determining the company's investment attractiveness.

AstraZeneca Corp. - AZN PEG Multiple (period 07/04/2022 - 11/10/2026)

Metric breakdowns and analytics for AstraZeneca PLC (AZN)

- share price and consensus valuation forecast:
Price Performance Chart AstraZeneca Plc|AZN - Price Target Chart
- stock exchange capitalization data:
Market Value AstraZeneca AB|AZN - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share AstraZeneca|AZN - Book Capitalization|Capitalization to Book Value Ratio astrazeneca.com|AZN - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient AstraZeneca PLC|AZN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio astrazeneca.com|AZN - Company Aggregate Debts|Debt to Net Assets AstraZeneca AB|AZN - Company Long-Term Debts|Company Short-Term Debts AstraZeneca|Interim Coverage Ratio astrazeneca.com
- financial results and valuation multiples details:
AZN - Net Income|Future Net Profit AstraZeneca PLC|AZN - Price to Earnings Ratio|Future Price to Earnings Multiple AstraZeneca Corp.|AZN - PEG Multiple|EV/EBITDA Multiple AstraZeneca AB|AZN - Operating profit before deduction of amortization|Earnings per one share for the last 12 months AstraZeneca|AZN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months astrazeneca.com|AZN - Earnings per share growth in current year|Projected earnings per share growth rate for next year AstraZeneca PLC
General company analysis:AstraZeneca PLC
Core merchandise of AstraZeneca Plc

The PEG ratio compares a stock's market value with net income dynamics, allowing investors to determine the extent of overpayment for future business growth. For AstraZeneca PLC (AZN), with its patent-protected R&D pipeline in oncology, this P/E to earnings growth ratio serves as an indicator of how effectively innovative blockbusters are capitalized, where values below one signal a fundamental undervaluation of the asset.

Competing companies

LLY (Lilly) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Abbvie ABBV|Novartis Pharma (NVS) - Price to Earnings Adjusted for Growth Rate|MRK - Price/Earnings to Growth Ratio|NVO: Price/Earnings to Growth Ratio|AMGN: PEG Multiple|Growth-Adjusted P/E Ratio PFE|SNY (Sanofi Aventis) - PEG Multiple|Bristol-Myers Squibb Co. (BMY) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio GSK plc (GSK)|takeda.com - Growth-Adjusted P/E Ratio|PEG Multiple TEVA (Teva Pharmaceutical Industries Limited)|Price to Net Income Growth Ratio Dr. Reddy's Laboratories Limited|Viatris Corp - PEG Multiple|ROIV - PEG Multiple|Zai Lab Limited (ZLAB) - Price/Earnings to Growth Ratio|BHC - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple COSM